文献速递炎症性肠病

如何治疗炎症性肠病以实现内镜缓解

How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-12-27

本文综述了在炎症性肠病(克罗恩病和溃疡性结肠炎)中,症状缓解、生物标志物正常化与内镜缓解之间常存在不一致,而内镜缓解与改善结局、减少住院和手术相关。文章讨论了在达标治疗策略中症状、生物标志物、影像和内镜的作用,并提供了临床实践中的实用指导。

要点

  • 内镜缓解与改善结局、减少住院和手术相关,是治疗的重要目标。
  • 症状缓解与内镜缓解常不一致,需结合生物标志物和内镜评估。
  • 达标治疗策略强调定期评估和序贯调整治疗直至达到内镜缓解。

核心结论

  • 炎症性肠病治疗应重视内镜缓解,因其与改善结局、减少住院和手术相关。
  • 达标治疗策略通过定期评估和序贯调整治疗以实现内镜缓解。

主要发现

  • 症状缓解、生物标志物正常化与内镜缓解之间可能存在不一致。
  • 内镜缓解与改善结局、减少住院和手术相关。

临床怎么用

  • 在临床实践中应结合症状、生物标志物、影像和内镜进行定期评估。
  • 采用达标治疗策略,序贯调整治疗直至达到内镜缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Crohn's disease and ulcerative colitis are heterogeneous conditions which may manifest with 1 or more of a constellation of abnormal symptoms, elevated biomarkers, and/or objective evidence of inflammation on endoscopic or cross-sectional evaluation. Whilst resolution of symptoms and restoration of quality of life is the primary goal for patients following a disease flare, there may be discordance between resolution of symptoms, biomarkers, and endoscopy. Increased emphasis is placed on the achievement of endoscopic remission, given it is associated with improved outcomes and reduction in hospitalization and surgeries. As the therapeutic armamentarium for inflammatory bowel disease does not achieve remission in all patients, there is greater emphasis on repetitive interval-based assessment of disease activity with sequential algorithmic treatment adjustments until endoscopic remission is achieved, in a so-called treat-to-target approach. We review the role of symptoms, biomarkers, imaging and endoscopy within treat-to-target algorithms and provide a practical guidance to their use in clinical practice.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Jairath V. How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission? Clin Gastroenterol Hepatol. 2019. PMID: 31887449. doi:10.1016/j.cgh.2019.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。